Overview

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

Status:
Terminated
Trial end date:
2018-12-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment (SSRI, SNRI or bupropion).
Phase:
Phase 2
Details
Lead Sponsor:
Taisho Pharmaceutical R&D Inc.